These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
199 related items for PubMed ID: 22532874
21. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER. Cancer Res; 2002 Jul 01; 62(13):3803-11. PubMed ID: 12097293 [Abstract] [Full Text] [Related]
22. A yeast two-hybrid system reconstituting substrate recognition of the von Hippel-Lindau tumor suppressor protein. Bex C, Knauth K, Dambacher S, Buchberger A. Nucleic Acids Res; 2007 Jul 01; 35(21):e142. PubMed ID: 17986458 [Abstract] [Full Text] [Related]
23. STAT3 inhibits the degradation of HIF-1alpha by pVHL-mediated ubiquitination. Jung JE, Kim HS, Lee CS, Shin YJ, Kim YN, Kang GH, Kim TY, Juhnn YS, Kim SJ, Park JW, Ye SK, Chung MH. Exp Mol Med; 2008 Oct 31; 40(5):479-85. PubMed ID: 18985005 [Abstract] [Full Text] [Related]
24. The VHL tumor suppressor: master regulator of HIF. Haase VH. Curr Pharm Des; 2009 Oct 31; 15(33):3895-903. PubMed ID: 19671042 [Abstract] [Full Text] [Related]
25. Parallel Regulation of von Hippel-Lindau Disease by pVHL-Mediated Degradation of B-Myb and Hypoxia-Inducible Factor α. Okumura F, Uematsu K, Byrne SD, Hirano M, Joo-Okumura A, Nishikimi A, Shuin T, Fukui Y, Nakatsukasa K, Kamura T. Mol Cell Biol; 2016 Jun 15; 36(12):1803-17. PubMed ID: 27090638 [Abstract] [Full Text] [Related]
26. The COP9/signalosome increases the efficiency of von Hippel-Lindau protein ubiquitin ligase-mediated hypoxia-inducible factor-alpha ubiquitination. Miyauchi Y, Kato M, Tokunaga F, Iwai K. J Biol Chem; 2008 Jun 13; 283(24):16622-31. PubMed ID: 18424433 [Abstract] [Full Text] [Related]
27. Nek1 phosphorylates Von Hippel-Lindau tumor suppressor to promote its proteasomal degradation and ciliary destabilization. Patil M, Pabla N, Huang S, Dong Z. Cell Cycle; 2013 Jan 01; 12(1):166-71. PubMed ID: 23255108 [Abstract] [Full Text] [Related]
28. VBP1 represses cancer metastasis by enhancing HIF-1α degradation induced by pVHL. Kim JA, Choi DK, Min JS, Kang I, Kim JC, Kim S, Ahn JK. FEBS J; 2018 Jan 01; 285(1):115-126. PubMed ID: 29121446 [Abstract] [Full Text] [Related]
29. Molecular cloning and characterization of the von Hippel-Lindau-like protein. Qi H, Gervais ML, Li W, DeCaprio JA, Challis JR, Ohh M. Mol Cancer Res; 2004 Jan 01; 2(1):43-52. PubMed ID: 14757845 [Abstract] [Full Text] [Related]
30. RHOBTB3 promotes proteasomal degradation of HIFα through facilitating hydroxylation and suppresses the Warburg effect. Zhang CS, Liu Q, Li M, Lin SY, Peng Y, Wu D, Li TY, Fu Q, Jia W, Wang X, Ma T, Zong Y, Cui J, Pu C, Lian G, Guo H, Ye Z, Lin SC. Cell Res; 2015 Sep 01; 25(9):1025-42. PubMed ID: 26215701 [Abstract] [Full Text] [Related]
31. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR. Zhou L, Yang H. PLoS One; 2011 Sep 01; 6(9):e23936. PubMed ID: 21949687 [Abstract] [Full Text] [Related]
32. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. Nature; 1999 May 20; 399(6733):271-5. PubMed ID: 10353251 [Abstract] [Full Text] [Related]
33. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Groulx I, Lee S. Mol Cell Biol; 2002 Aug 20; 22(15):5319-36. PubMed ID: 12101228 [Abstract] [Full Text] [Related]
34. Genetic deletion of the long isoform of the von Hippel-Lindau tumour suppressor gene product alters microtubule dynamics. Frew IJ, Smole Z, Thoma CR, Krek W. Eur J Cancer; 2013 Jul 20; 49(10):2433-40. PubMed ID: 23541568 [Abstract] [Full Text] [Related]
35. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Maynard MA, Ohh M. Am J Nephrol; 2004 Jul 20; 24(1):1-13. PubMed ID: 14654728 [Abstract] [Full Text] [Related]
36. Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway. Ivanova AV, Ivanov SV, Danilkovitch-Miagkova A, Lerman MI. J Biol Chem; 2001 May 04; 276(18):15306-15. PubMed ID: 11278694 [Abstract] [Full Text] [Related]
37. VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations. Rechsteiner MP, von Teichman A, Nowicka A, Sulser T, Schraml P, Moch H. Cancer Res; 2011 Aug 15; 71(16):5500-11. PubMed ID: 21715564 [Abstract] [Full Text] [Related]
38. Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor. Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G. Biochem Biophys Res Commun; 2002 Jun 14; 294(3):700-9. PubMed ID: 12056827 [Abstract] [Full Text] [Related]
39. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor. Nyhan MJ, O'Sullivan GC, McKenna SL. Biochem Soc Trans; 2008 Jun 14; 36(Pt 3):472-8. PubMed ID: 18481984 [Abstract] [Full Text] [Related]
40. TCTP increases stability of hypoxia-inducible factor 1α by interaction with and degradation of the tumour suppressor VHL. Chen K, Chen S, Huang C, Cheng H, Zhou R. Biol Cell; 2013 May 14; 105(5):208-218. PubMed ID: 23387829 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]